Variability in the extent of del(5q) and its clinical implication in myelodysplastic syndromes (MDS).

被引：0
|
作者：
Zemanova, Zuzana
Brezinova, Jana
Svobodova, Karla
Lhotska, Halka
Izakova, Silvia
Sarova, Iveta
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e19025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19025
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Myelodysplastic syndromes 5q deletion in childhood
    Iriani, A.
    LEUKEMIA RESEARCH, 2013, 37 : S93 - S93
  • [32] Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring
    Jaedersten, Martin
    Karsan, Aly
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (02): : 177 - 180
  • [33] Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q
    Nimer, Stephen D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2576 - 2582
  • [34] Gene expression profiling in patients with myelodysplastic syndromes, including patients with the del(5q)
    Boultwood, J.
    LEUKEMIA RESEARCH, 2009, 33 : S3 - S4
  • [35] The questions on megakaryopoiesis in MDS patients with del(5q)
    Neuwirtova, R.
    Jonasova, A.
    Cermak, J.
    Vondrakova, J.
    Hochova, I.
    Jungova, A.
    Belohlavkova, P.
    Siskova, M.
    Kadlckova, E.
    Cerna, O.
    Smolikova, A.
    Polonyova, E.
    Bruchova, H.
    Zemanova, Z.
    Mikulenkova, D.
    LEUKEMIA RESEARCH, 2009, 33 : S105 - S105
  • [36] MDS with isolated del(5q) and internuclear bridging
    Xu, Zhaodong
    McGowan-Jordan, Jean
    BLOOD, 2017, 129 (16) : 2333 - 2333
  • [37] Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
    A A N Giagounidis
    U Germing
    S Haase
    B Hildebrandt
    B Schlegelberger
    C Schoch
    L Wilkens
    M Heinsch
    H Willems
    M Aivado
    C Aul
    Leukemia, 2004, 18 : 113 - 119
  • [38] Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31
    Giagounidis, AAN
    Germing, U
    Haase, S
    Hildebrandt, B
    Schlegelberger, B
    Schoch, C
    Wilkens, L
    Heinsch, M
    Willems, H
    Aivado, M
    Aul, C
    LEUKEMIA, 2004, 18 (01) : 113 - 119
  • [39] EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Santini, V.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Ozawa, K.
    Goldberg, S. L.
    Weaver, J.
    Sugrue, M. M.
    LEUKEMIA RESEARCH, 2017, 55 : S51 - S51
  • [40] SELECTIVE EFFECT OF LENALIDOMIDE ON CELL CYCLE AND INOSITIDE-DEPENDENT ERYTHROID SIGNALLING IN DEL(5Q) CELLS AND MYELODYSPLASTIC SYNDROMES (MDS)
    Follo, M. Y.
    Mongiorgi, S.
    Clissa, C.
    Poli, A.
    Lonetti, A.
    Stanzani, M.
    Cappellini, A.
    Billi, A. M.
    Manzoli, L.
    Cocco, L.
    Finelli, C.
    HAEMATOLOGICA, 2014, 99 : 85 - 85
12345